Cohance Lifesciences Reports Q1 FY27 Results; Plans Further Equity Stake in Sapala Organics

Cohance Lifesciences Reports Q1 FY27 Results; Plans Further Equity Stake in Sapala Organics​

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, announced its unaudited financial results for the first quarter of fiscal year 2027 (Q1 FY27) ended June 30, 2026. The company also confirmed plans to acquire a further equity stake in its subsidiary, Sapala Organics Private Limited, as part of an ongoing reorganization designed to strengthen the nucleic acid business.

The results reflected a period of strategic transition and focused execution across business segments, with management guiding that Q1 was a "bottoming out quarter" for the company.

Financial Performance Highlights (Q1 FY27)​

The company reported consolidated revenue from operations of ₹4,223 million for the quarter ended June 30, 2026. Standalone results showed revenue from operations at ₹3,599 million.

Key financial metrics, as detailed below, include:


Q1 FY27 Standalone Financials:
The standalone business generated revenue of ₹3,599 million and achieved an Adjusted EBITDA margin of 9.2%. The company’s commitment to core R&D and manufacturing was evident in the investment, with capital expenditure during the quarter reported at approximately ₹598 million.

Consolidated Financials:
The consolidated entity reported a loss of (₹452) million after tax for Q1 FY27, reflecting lower revenue base and negative operating leverage due to subsidiary consolidation. The company maintained a healthy liquidity position, with net cash standing at approximately ₹2,512 million as of June 30, 2026.

Strategic Focus: Unifying the Nucleic Acid Business​

In significant strategic movement, Cohance Lifesciences announced plans for a reorganization involving Sapala Organics Private Limited, one of the company’s subsidiaries.

The company intends to enter into amendment agreements with the selling shareholders of Sapala to solidify a unified operating model for its nucleic acid business. Following previous acquisitions completed in 2024, Cohance will acquire an additional 21% equity stake following Sapala's financial results for the year ending March 31, 2027. The remaining 28% of the equity stake is scheduled to be acquired after Sapala’s results for the year ending March 31, 2030.

Dr. P. Yella Reddy, who has led Sapala, will continue as Chief Executive Officer of Sapala until March 31, 2029 and will lead Cohance's Nucleic Acid business. This reorganization is intended to strengthen integration across research, development, and manufacturing for the combined nucleic acid platform.

Business and Operational Updates​

Management stated that Q1 performance was "in line with commentary," noting declines in revenue were attributed to shipment and order phasing, unfavorable product mix, and subsidiary consolidation. The company expressed confidence in a turnaround in the second half of FY27, supported by secured orders and pipeline progression.

Key Business Highlights:

• Pharma CDMO & ADC: Two recently commercialized molecules are scheduled for delivery across Q2 and Q3 of FY27. The ADCs portfolio continues to grow, with two unique commercial ADC payload supplies delivered to large innovators.
• Nucleic Acids (Sapala): Sapala entered FY27 with meaningful order visibility from global pharmaceutical and biotechnology customers, including a significant order for a European clinical-stage company. The new amidites facility is complete, and product qualification has commenced.
• API+: This segment remains resilient, supported by niche APIs, backward integration, and a healthy order book. Operations at the Nacharam formulation facility have resumed.
• ESG and Recognition: Cohance's sustainability assessment score progressed from Silver to Gold via EcoVadis, reflecting strong environmental, social, and governance performance. The company also received the British Safety Council International Safety Award 2026 (Merit) for two API sites and two CDMO sites.

The management emphasized that the focus remains on customer conversion, predictable delivery, quality, safety, and improved utilization across the Cohance platform.

COHANCE Stock Price Movement​

Cohance Lifesciences Limited shares closed today after edging higher by 0.82%, settling at ₹429.45, driven by post-market buying interest. The stock delivered a steady performance on a volume of 365,514 shares, trading within the day's range of ₹422.5 to ₹431.9.